Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with (131)I-MIP-1095

PURPOSE: Prostate-specific membrane antigen (PSMA)-targeting radioligand therapy (RLT) was introduced in 2011. The first report described the antitumor and side effects of a single dose. The aim of this analysis was to evaluate toxicity and antitumor activity after single and repetitive therapies. M...

Full description

Saved in:
Bibliographic Details
Published in:Eur J Nucl Med Mol Imaging
Main Authors: Afshar-Oromieh, Ali, Haberkorn, Uwe, Zechmann, Christian, Armor, Thomas, Mier, Walter, Spohn, Fabian, Debus, Nils, Holland-Letz, Tim, Babich, John, Kratochwil, Clemens
Format: Artigo
Language:Inglês
Published: Springer Berlin Heidelberg 2017
Subjects:
Original Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5397661/
https://ncbi.nlm.nih.gov/pubmed/28280855
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00259-017-3665-9
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items